Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review
This is the first report of a NSCLC patient with a novel <i>SV2B-ALK</i>, <i>EML4-ALK</i> double-fusion benefiting from alectinib. Alectinib may be an effective therapeutic option for both primary and metastatic lesions including brain metastases in the late-line setting in NSCLC patients with double-<i>ALK</i> fusion.
Authors
- Menglan Zhang (ORCID: https://orcid.org/0000-0002-0997-267X)
- Tao Dai (ORCID: https://orcid.org/0009-0002-7908-2231)
- Mingming Yuan (ORCID: https://orcid.org/0000-0001-5475-7736)
- Yujuan Qi (ORCID: https://orcid.org/0000-0002-0098-6813)
- Dingrong Zhong (ORCID: https://orcid.org/0000-0002-6229-1830)
- Ruiying Jiang
- Ye Wang (ORCID: https://orcid.org/0000-0002-8336-1076)
- Xiaowei Wang (ORCID: https://orcid.org/0000-0003-0940-1882)
- Qianqian Feng (ORCID: https://orcid.org/0009-0009-6537-4904)
- Chen Huang (ORCID: https://orcid.org/0000-0002-2407-9716)
- Rongrong Chen (ORCID: https://orcid.org/0000-0002-4489-4179)
- Liyan Bai (ORCID: https://orcid.org/0000-0003-2542-0442)
- Yun Niu (ORCID: https://orcid.org/0009-0006-5965-8917)
- Bei Wang (ORCID: https://orcid.org/0000-0003-2567-4178)
Institutions
- China-Japan Friendship Hospital (CN)
- Qinghai Provincial Peoples Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-12-13
- DOI
- https://doi.org/10.3389/fonc.2024.1453259
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.68